Ozempic Price by Country (2026): Verified Four-Dose Data
Weight Loss Provider Guide Editorial Team
Last verified: August 3, 2026 · Dataset version: 1.0.0 · Comparison unit: four weekly 1 mg Ozempic injection doses, 4 mg total
On August 3, 2026, the U.S. manufacturer list price for an Ozempic pen delivering four weekly 1 mg doses was $1,027.51. That was 8.11 times the $126.62 median of eight non-U.S. published benchmarks in this dataset. Australia had the lowest fully comparable benchmark in the dataset at $92.07; Ontario's public formulary benchmark was the highest outside the United States in the dataset at $162.49. NovoCare also published the same $1,027.51 U.S. list price for injection pens containing 2 mg, 4 mg, and 8 mg of semaglutide, creating a fourfold spread in list price per milligram of total pen contents.
The qualification belongs with the quote: these are published price benchmarks, not universal patient costs, and they are not all the same kind of price. The U.S. row is a manufacturer list price before discounts or rebates. Other rows are Drug Tariff, formulary, government package, or pharmacy retail benchmarks. Every row states which.
What are the headline Ozempic price statistics?
Answer: The core result is a $1,027.51 U.S. manufacturer list price against a $126.62 median of eight non-U.S. published benchmarks, a multiple of 8.11×. Australia is the lowest fully comparable benchmark in the dataset at $92.07.
| Metric | Value |
|---|---|
| U.S. manufacturer list price for the four-dose 1 mg pen | $1,027.51 |
| Median of eight non-U.S. published benchmarks | $126.62 |
| U.S. list price ÷ non-U.S. median | 8.11× |
| Lowest fully comparable benchmark | Australia — $92.07 |
Source: Weight Loss Provider Guide Research, verified August 3, 2026. USD conversions use European Central Bank reference rates for August 3, 2026.
Ozempic price by country: what does a four-dose 1 mg pen cost?
Answer: The eight fully comparable non-U.S. benchmarks ranged from $92.07 in Australia to $162.49 for Ontario's public formulary. Their median was $126.62. The U.S. manufacturer list price for the same four-dose 1 mg specification was $1,027.51.
Every included row maps to a package delivering four weekly 1 mg injection doses, 4 mg total. “Comparable” here means the dose and package can be reproduced from the source. It does not mean the legal or economic meaning of each published price is identical.
| # | Market | Local benchmark | What the price represents | USD equivalent | USD per weekly dose | U.S. list price ÷ benchmark | Primary or authoritative source |
|---|---|---|---|---|---|---|---|
| 1 | Australia | A$131.40 | PBS Dispensed Price for Maximum Quantity | $92.07 | $23.02 | 11.16× | PBS item 14163K |
| 2 | United Kingdom | £73.25 | NHS Drug Tariff price | $98.67 | $24.67 | 10.41× | NICE BNF |
| 3 | Sweden | SEK 1,049.02 | FASS package price within restricted high-cost protection | $110.16 | $27.54 | 9.33× | FASS |
| 4 | Netherlands | €105.60 | National package benchmark, excluding pharmacy delivery costs | $121.81 | $30.45 | 8.44× | Medicijnkosten |
| 5 | Switzerland | CHF 106.20 | Federal Office of Public Health public price | $131.44 | $32.86 | 7.82× | BAG pricing decision |
| 6 | Denmark | DKK 855.80 | Pharmacy package price including VAT and fee; 14-day period | $132.06 | $33.02 | 7.78× | Medicinpriser, product 582611 |
| 7 | Norway | NOK 1,269.70 | Maximum pharmacy retail price | $133.19 | $33.30 | 7.71× | Felleskatalogen |
| 8 | Canada (Ontario benchmark) | C$227.94 | Ontario Drug Benefit Price | $162.49 | $40.62 | 6.32× | Ontario Drug Benefit Formulary, DIN 02471469 |
| 9 | United States | $1,027.51 | Manufacturer list price before discounts or rebates | $1,027.51 | $256.88 | 1.00× | NovoCare |
Source line: local prices come from the linked government, formulary, national medicines-reference, and manufacturer pages. USD equivalents use ECB rates dated August 3, 2026. Local prices are the primary data; converted values are a dated comparison layer.
| Statistic | Result |
|---|---|
| Non-U.S. median | $126.62 |
| Non-U.S. mean | $122.74 |
| Non-U.S. range | $92.07–$162.49 |
| U.S. list price ÷ non-U.S. median | 8.11× |
| U.S. premium over the median | 711.46% |
| U.S. list price ÷ Australia | 11.16× |
| U.S. list price ÷ Ontario benchmark | 6.32× |
| U.S. list price per weekly 1 mg dose | $256.88 |
| Non-U.S. median benchmark per weekly 1 mg dose | $31.66 |
Source line: Weight Loss Provider Guide Research calculations from the unrounded local-price and ECB-conversion values in Table 1. Displayed results are rounded to two decimal places. The median and mean use the eight non-U.S. rows.
The portable version is simple: the U.S. manufacturer list price works out to $256.88 per weekly 1 mg dose; the median non-U.S. published benchmark works out to $31.66.
Which market has the lowest comparable Ozempic price?
Answer: Australia had the lowest fully comparable benchmark in this dataset at A$131.40, equal to $92.07 on the conversion date. France's observed official price converted slightly lower, to $89.51, but France is excluded because its public package fields do not reconcile to the four-dose standard.
That distinction matters. “Australia is lowest in this dataset” is supported. “Australia has the cheapest Ozempic in the world” is not.
Why does one U.S. list price cover pens containing 2 mg, 4 mg, and 8 mg?
Answer: NovoCare published the same $1,027.51 list price for all three U.S. Ozempic injection pens. The current FDA label identifies those pens as containing 2 mg, 4 mg, and 8 mg of semaglutide, which produces a 4.00× spread in list price per milligram of total pen contents.
| Labeled pen | Current FDA presentation | Total semaglutide in pen | Doses described by FDA | NovoCare list price | List price per mg in pen |
|---|---|---|---|---|---|
| 0.25 mg / 0.5 mg dose pen | 2 mg/3 mL | 2 mg | Four 0.25 mg plus two 0.5 mg doses, or four 0.5 mg doses | $1,027.51 | $513.76 |
| 1 mg dose pen | 4 mg/3 mL | 4 mg | Four 1 mg doses | $1,027.51 | $256.88 |
| 2 mg dose pen | 8 mg/3 mL | 8 mg | Four 2 mg doses | $1,027.51 | $128.44 |
Source line: pen contents and doses come from the FDA prescribing information revised May 2026. List prices come from NovoCare. Per-milligram figures are original calculations.
Two source-page conflicts are recorded rather than hidden:
- NovoCare labels the 0.25/0.5 mg injection pen as 1.5 mL, while the current FDA label identifies the U.S. pen as 2 mg/3 mL. This page uses the FDA label for package contents and volume.
- On August 3, 2026, the NovoCare page also rendered a second set of $997.58 values below the clearly labeled $1,027.51 bullets, without explaining the difference. This page uses the top-line $1,027.51 list price and records the duplicate so the source can be checked honestly.
Flat package pricing is not unique to the United States. Switzerland's Federal Office of Public Health explicitly applies the same CHF 106.20 public price to its 2 mg/1.5 mL and 4 mg/3 mL Ozempic packages.
| Market | Published price | Verified pen contents at that price | Highest price per mg ÷ lowest price per mg |
|---|---|---|---|
| United States | $1,027.51 | 2 mg, 4 mg, and 8 mg | 4.00× |
| Switzerland | CHF 106.20 | 2 mg and 4 mg | 2.00× |
Source line: U.S. list price from NovoCare and U.S. contents from FDA labeling; Swiss price and contents from the Federal Office of Public Health decision. This comparison is based on total pen contents, not patient out-of-pocket cost.
The supported conclusion is precise: the U.S. list-price-per-milligram spread is fourfold across its three injection pens, but flat Ozempic package pricing also exists in Switzerland.
What do these Ozempic prices show—and what do they not show?
Answer: The dataset shows nine published benchmarks attached to one standardized injection presentation on one date. It does not show confidential net payer prices, universal patient costs, pharmacy stock, eligibility, or lawful access for a person in another jurisdiction.
Published benchmark is not net price. The U.S. Government Accountability Office has documented how confidential rebates and discounts cloud international drug-price comparisons. Public pages do not reveal every transaction price, and a list-price comparison cannot be relabeled as a net-price comparison. See the GAO report.
Published benchmark is not patient cost. Australia's PBS page lists a DPMQ of A$131.40 and a separate A$25 general patient charge. The PBS explains that the DPMQ is the medicine's maximum-quantity cost benchmark and that the government contribution depends on the patient co-payment and scheme rules. See the PBS item and PBS fee explanation.
The same column contains different price layers. The U.S. row is a manufacturer list price. The U.K. row is a Drug Tariff price. Ontario supplies both a Drug Benefit Price and a lower “Amount MOH Pays” field; this dataset uses the Drug Benefit Price because that is the named package benchmark and records the distinction. Norway's source defines its figure as a maximum pharmacy retail price. Denmark's package price includes VAT and a fee.
A published price is not access. None of the figures establishes prescribing eligibility, reimbursement eligibility, residency rules, pharmacy inventory, import legality, or clinical appropriateness.
How was the Ozempic price-by-country dataset built?
Answer: The dataset fixes one comparison unit, verifies the exact package and local price, labels the price basis, converts every non-U.S. figure with one dated ECB table, and excludes any row that cannot survive the package-matching rule. Every derived statistic can be reproduced from the local price, exchange rate, and formula below.
The comparison unit
The standard is four weekly 1 mg Ozempic injection doses, 4 mg total. The current FDA label identifies the U.S. presentation as 4 mg/3 mL for four 1 mg doses. Current EMA product information likewise describes a 3 mL pen delivering four 1 mg doses.
This dataset covers the Ozempic injection pen only. Ozempic tablets, single-dose syringes, Wegovy, Rybelsus, compounded semaglutide, seller-specific online-pharmacy prices, and import prices are outside scope.
Inclusion rule
A row enters the calculated comparison only when all five conditions are met:
- A durable government, national formulary, national medicines-reference, or manufacturer source is available.
- The source identifies the exact strength and package.
- The package can be mapped to four weekly 1 mg doses without an unsupported assumption.
- The published price has a named basis.
- The source and price were verified on the release date or carry a stated effective period covering that date.
Source hierarchy
Government pricing portals and public formularies come first. National medicines references and compendia come next when they are the authoritative public source for the market. The manufacturer's list-price page is used for the United States because the U.S. figure being compared is the manufacturer's own list price.
FASS and Felleskatalogen are national medicines compendia rather than government pricing portals, and NovoCare is the manufacturer source. Their source types are stated instead of being flattened into one label.
Currency conversion
All currencies are quoted against the euro on the ECB page. The formula is:
For a non-euro currency:
USD equivalent = local price ÷ local-currency units per EUR × USD per EUR
For a euro price:
USD equivalent = euro price × USD per EUR
| Currency | Units per EUR on August 3, 2026 |
|---|---|
| U.S. dollar | 1.1535 |
| Pound sterling | 0.85633 |
| Swedish krona | 10.9845 |
| Swiss franc | 0.9320 |
| Danish krone | 7.4749 |
| Norwegian krone | 10.9965 |
| Australian dollar | 1.6463 |
| Canadian dollar | 1.6181 |
Source line: European Central Bank reference rates, August 3, 2026. The ECB says the rates are published for information purposes and discourages using them as transaction rates.
Comparability grading
- Grade A: the source supports the four-dose 1 mg standard. Included in Table 1 and all calculated statistics.
- Grade B: a public price exists, but the package cannot be reconciled to the standard without an unsupported assumption. Reported separately and excluded from the median, mean, range, per-dose calculations, and “lowest comparable” conclusion.
- Not published: the current authoritative price or exact package could not be verified cleanly enough for this release.
Calculation rules
The median uses the eight unrounded non-U.S. USD equivalents. The mean uses the same eight values. Multiples are calculated from unrounded values and rounded only for display. A refresh takes a new ECB snapshot and recomputes every USD figure, display order, average, multiple, and headline number.
What the method deliberately does not do
There is no purchasing-power-parity adjustment in the headline table because that answers a different question. There is no average across price types because a manufacturer list price and a public formulary amount do not become comparable merely by averaging them. There are no online-pharmacy or importer prices because seller inventory, shipping, markup, and access rules would turn a country-system dataset into a shopping table.
What is the source and price basis for each market?
Answer: Every row has one exact package, one named source, and one stated price layer. These notes are the source record behind Table 1 and state the caveat attached to each figure.
Australia — A$131.40
The Pharmaceutical Benefits Scheme item identifies semaglutide 1.34 mg/mL in one 3 mL pen and lists a DPMQ of A$131.40. It separately lists an A$25 general patient charge and restricts the item to streamlined-authority use for type 2 diabetes. Price basis: PBS Dispensed Price for Maximum Quantity, not a universal patient cost and not simply “what the government pays.”
United Kingdom — £73.25
The NICE British National Formulary lists the Ozempic 1 mg/0.74 mL, 3 mL pre-filled pen at a £73.25 Drug Tariff price. Price basis: NHS Drug Tariff price.
Sweden — SEK 1,049.02
FASS identifies the 1 mg package as one pen containing four doses and lists SEK 1,049.02. The page says the medicine is included in Sweden's high-cost protection with a restriction tied to type 2 diabetes. Price basis: published FASS package price within a restricted reimbursement listing.
Netherlands — €105.60
Medicijnkosten, operated by the National Health Care Institute, lists the 1 mg/dose 3 mL pen at €105.60. The page says the figure excludes pharmacy delivery costs and is the amount charged to the deductible per package, with reimbursement conditions attached. Price basis: national package and deductible benchmark, excluding delivery costs.
Switzerland — CHF 106.20
The Federal Office of Public Health decision lists the 4 mg/3 mL FixDose package at a CHF 106.20 public price. The same decision applies flat pricing to the 2 mg/1.5 mL DualDose package. Price basis: BAG public price under the stated reimbursement limitation.
Denmark — DKK 855.80
Medicinpriser identifies product 582611 as a four-dose 1 mg pen at DKK 855.80. The page states that the package price includes VAT and the prescription-handling fee and gives a price period of August 3 through August 16, 2026. Price basis: pharmacy package price for the current 14-day period.
Norway — NOK 1,269.70
Felleskatalogen lists the 3 mL four-dose 1 mg pen at NOK 1,269.70 and separately lists an eight-dose pen at NOK 2,481.20. Its price glossary defines the displayed price as the maximum pharmacy retail price. Price basis: maximum pharmacy retail price for the four-dose item.
Canada — Ontario benchmark of C$227.94
The Ontario Drug Benefit Formulary lists DIN 02471469, Ozempic 1.34 mg/mL in a 3 mL pen, at a Drug Benefit Price of C$227.94. The same row separately displays an “Amount MOH Pays” of C$78.1410 and marks the product Limited Use. Price basis: Ontario Drug Benefit Price; not a Canada-wide retail price and not the separate ministry-payment field.
United States — $1,027.51
NovoCare defines list price as the manufacturer's price before discounts or rebates and lists $1,027.51 for the 0.25/0.5 mg, 1 mg, and 2 mg injection pens. The source-page conflicts described above remain part of the source record. Price basis: manufacturer list price before discounts or rebates.
Which countries were excluded from the calculated comparison?
Answer: France is reported as a Grade B observed price because its official fields conflict with the four-dose package standard. Germany and Japan are not assigned price figures in version 1.0.0 because a current, openly verifiable, exact-package benchmark did not meet the publication rule.
| Market | What was verified | Publication decision |
|---|---|---|
| France | Official price of €77.60 including the dispensing fee, equal to $89.51 at the ECB rate; public page also displays a 1.5 mL cartridge and a 1 mg dose in 0.74 mL | Report the observed price, but exclude it from all four-dose statistics because the displayed package fields imply about two doses while current EMA information describes the four-dose 1 mg pen as 3 mL |
| Germany | No current, freely accessible authoritative exact-package benchmark was verified for this release | Do not publish a German price in version 1.0.0 |
| Japan | No current one-pen presentation delivering four 1 mg doses was verified in the official source set used for this release | Do not publish a Japanese four-dose price or force a multi-pen normalization into the main comparison |
Source line for France: French Public Database of Medicines and current EMA Ozempic product information. Germany and Japan remain outside the dataset rather than being filled with secondary or seller-specific figures.
France is the consequential exclusion. Its €77.60 observed figure converts below Australia's benchmark, but including it would require asserting a four-dose package that the French page's displayed fields do not support. The page reports the conflict instead of deciding the answer in advance.
Why do published Ozempic prices differ by market?
Answer: The dataset cannot isolate one cause for the international gap, but it can show exactly which price layers are being compared. The nine included rows span manufacturer list, Drug Tariff, public formulary, government package, maximum pharmacy retail, and reimbursement-linked package prices.
The World Health Organization's guideline on pharmaceutical pricing policies describes multiple tools countries use, including internal and external reference pricing and value-based approaches. The table above does not score those systems or claim one policy produced each number.
The other reason the gap cannot be reduced to one clean causal figure is opacity. GAO's international comparison found that confidential rebates and discounts can make publicly available gross prices diverge from net prices. That is why this page states the source layer in every row and stops at the evidence the public sources actually provide.
What are the limitations of this Ozempic price comparison?
Answer: This is a reproducible comparison of published benchmarks, not a global census or a measure of net payer or patient cost. The limits are part of the dataset and should travel with any quoted number.
The price concepts are not economically identical. A manufacturer list price, Drug Tariff price, formulary price, and maximum pharmacy retail price answer different institutional questions.
Net prices are not fully observable. Public pages do not expose every rebate, discount, concession, or negotiated transaction price.
These are not universal patient costs. Insurance, reimbursement eligibility, deductibles, co-payments, exemptions, pharmacy fees, and residency rules can change what an individual pays.
Currency conversion moves. Every USD number depends on the August 3, 2026 ECB snapshot. The local-currency price is the more durable field.
Denmark's price is time-boxed. Its source explicitly covers August 3 through August 16, 2026.
Ontario is a provincial benchmark. It is not one national Canadian retail price.
France is not in the calculated statistics. Its official price is visible, but its displayed package fields fail the four-dose comparison rule.
Germany and Japan are not backfilled with weaker evidence. Version 1.0.0 leaves those values blank rather than publishing secondary or seller-specific numbers as national facts.
This is a sample, not a claim about every country. Australia is the lowest fully comparable benchmark among the markets included here, not a proven world minimum.
This is an educational pricing reference, not medical, legal, insurance, or importation advice. A price does not establish clinical appropriateness, prescription eligibility, reimbursement, lawful access, or medicine quality.
Frequently asked questions about Ozempic prices by country
Answer: The questions below cover the most common follow-ups: the cheapest comparable benchmark, the U.S. multiple, the meaning of the price column, Canada, Europe, France's exclusion, access, the U.S. label, and the update schedule.
How much does Ozempic cost in other countries?
For a benchmark standardized to four weekly 1 mg injection doses, the eight non-U.S. published prices in this dataset ranged from $92.07 in Australia to $162.49 for Ontario's public formulary. Their median was $126.62. The U.S. manufacturer list price for the same four-dose specification was $1,027.51.
Which country has the cheapest comparable Ozempic price?
Australia had the lowest fully comparable benchmark in this dataset: A$131.40, equal to $92.07 at the August 3, 2026 ECB reference rate. France's official €77.60 observed price converted to $89.51, but France was excluded because its public package fields did not reconcile to the four-dose comparison standard.
How much more does Ozempic cost in the United States?
The $1,027.51 U.S. manufacturer list price was 8.11 times the $126.62 non-U.S. median and 11.16 times Australia's benchmark. Per weekly 1 mg dose, that is $256.88 at U.S. list price versus a $31.66 median published benchmark outside the United States.
Are these list prices or what patients actually pay?
They are published benchmarks of different types, and the table labels each one. The U.S. figure is a manufacturer list price; other rows include a Drug Tariff price, public package prices, pharmacy retail prices and formulary amounts. None should be read as a universal patient out-of-pocket cost.
Why does the U.S. list price stay the same across different pen strengths?
NovoCare published the same $1,027.51 list price for U.S. injection pens containing 2 mg, 4 mg and 8 mg of semaglutide. That produces list prices of $513.76, $256.88 and $128.44 per milligram of total pen contents, a fourfold spread. The source does not explain the pricing decision.
How much is Ozempic in Canada?
The Ontario Drug Benefit Formulary lists the 1.34 mg/mL, 3 mL pen at C$227.94, equal to $162.49 at the August 3, 2026 ECB rate. That is Ontario's Drug Benefit Price, not one national Canadian retail price and not the separate amount the page reports as paid by Ontario's Ministry of Health.
Is Ozempic cheaper in Europe?
At the published-price layer used here, the six fully comparable European benchmarks ranged from $98.67 in the United Kingdom to $133.19 in Norway, far below the $1,027.51 U.S. manufacturer list price. This does not establish the difference in confidential net payer prices or individual patient costs.
Why is France not included in the main comparison?
France's public medicines database lists €77.60 including the dispensing fee, but it also displays a 1.5 mL cartridge and a 1 mg dose in 0.74 mL. Those fields imply about two doses, while current EMA product information describes the four-dose 1 mg pen as 3 mL. The French price is reported separately rather than forced into the four-dose calculation.
Can I buy Ozempic at these prices while traveling?
The table does not establish pharmacy stock, prescribing eligibility, reimbursement eligibility, residency rules or lawful cross-border access. It is a pricing reference, not guidance on obtaining or importing prescription medicine.
Is Ozempic FDA-approved for weight loss?
The current U.S. FDA label for Ozempic injection does not list weight loss as an indication. It lists glycemic control in adults with type 2 diabetes and specified cardiovascular and kidney risk-reduction indications in defined adults with type 2 diabetes.
How often is this dataset updated?
Every source should be rechecked monthly, with a dated full release at least quarterly and an immediate update when a price, package or source field changes. The Last verified date should change only after the sources and dependent calculations have actually been rerun.
How to cite this page
Answer: The formats below keep the page title, editorial byline, verification date, publication name, and URL together so the dataset can be identified accurately.
APA
Weight Loss Provider Guide Editorial Team. (2026, August 3). Ozempic price by country (2026): Verified four-dose data. Weight Loss Provider Guide Research. https://weightlossproviderguide.com/research/ozempic-price-by-country/
Chicago
Weight Loss Provider Guide Editorial Team. “Ozempic Price by Country (2026): Verified Four-Dose Data.” Weight Loss Provider Guide Research. Last verified August 3, 2026. https://weightlossproviderguide.com/research/ozempic-price-by-country/
In-text attribution
according to an August 2026 nine-market pricing analysis by Weight Loss Provider Guide Research
Suggested table caption
Ozempic four-dose 1 mg injection benchmarks by market, converted to USD using European Central Bank reference rates dated August 3, 2026. Source: Weight Loss Provider Guide Research.
Caveat to carry with the data
Figures are published benchmarks of different price types—including manufacturer list, Drug Tariff, formulary, government package, and pharmacy retail prices—and are not interchangeable with patient out-of-pocket or confidential net payer costs.
What related Ozempic and GLP-1 research is available?
Answer: The related pages below separate U.S. price history, insurer authorization rules, state coverage mandates, and Medicare spending into their own source-backed datasets.
- Ozempic price history: the U.S. list-price series, 2017–2027
- GLP-1 prior authorization requirements by insurer
- GLP-1 insurance coverage mandates by state
- Medicare GLP-1 spending by state
How are corrections and data changes recorded?
Answer: Accepted source-backed corrections and release changes are recorded by date and version. A correction does not change the Last verified date unless the full source set and dependent calculations are rerun.
| Date | Version | Change |
|---|---|---|
| August 3, 2026 | 1.0.0 | Initial nine-market release. Standardized to four weekly 1 mg injection doses; ECB conversion frozen to August 3, 2026; France reported separately; U.S. and Swiss flat-pricing comparison added; source-page conflicts documented. |
Source: Weight Loss Provider Guide Research release history, version 1.0.0.
Compiled and verified by: Weight Loss Provider Guide Editorial Team
Last verified: August 3, 2026
Dataset version: 1.0.0
Independence statement: Weight Loss Provider Guide Research is the site's independent research and reference section. This page contains no affiliate links, provider recommendations, advertisements, lead forms, or commercial calls to action.
Scope and safety notice: This dataset covers Ozempic injection pricing. The current U.S. FDA injection label lists glycemic-control and specified cardiovascular and kidney risk-reduction indications in adults with type 2 diabetes; it does not list weight loss as an indication. Treatment decisions belong with a licensed clinician or pharmacist, and coverage questions belong with the applicable insurer or public program.
